JP2014521658A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521658A5
JP2014521658A5 JP2014523092A JP2014523092A JP2014521658A5 JP 2014521658 A5 JP2014521658 A5 JP 2014521658A5 JP 2014523092 A JP2014523092 A JP 2014523092A JP 2014523092 A JP2014523092 A JP 2014523092A JP 2014521658 A5 JP2014521658 A5 JP 2014521658A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
amount
laquinimod
day
glatiramer acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014523092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521658A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/048684 external-priority patent/WO2013016684A1/en
Publication of JP2014521658A publication Critical patent/JP2014521658A/ja
Publication of JP2014521658A5 publication Critical patent/JP2014521658A5/ja
Withdrawn legal-status Critical Current

Links

JP2014523092A 2011-07-28 2012-07-27 ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 Withdrawn JP2014521658A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512808P 2011-07-28 2011-07-28
US61/512,808 2011-07-28
PCT/US2012/048684 WO2013016684A1 (en) 2011-07-28 2012-07-27 Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016230818A Division JP2017081930A (ja) 2011-07-28 2016-11-29 ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療

Publications (2)

Publication Number Publication Date
JP2014521658A JP2014521658A (ja) 2014-08-28
JP2014521658A5 true JP2014521658A5 (enExample) 2015-09-17

Family

ID=47597714

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014523092A Withdrawn JP2014521658A (ja) 2011-07-28 2012-07-27 ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
JP2016230818A Withdrawn JP2017081930A (ja) 2011-07-28 2016-11-29 ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016230818A Withdrawn JP2017081930A (ja) 2011-07-28 2016-11-29 ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療

Country Status (19)

Country Link
US (3) US20130029916A1 (enExample)
EP (1) EP2736335A4 (enExample)
JP (2) JP2014521658A (enExample)
KR (1) KR20140054166A (enExample)
CN (2) CN103781354A (enExample)
AU (2) AU2012286699A1 (enExample)
BR (1) BR112014002095A2 (enExample)
CA (1) CA2843433A1 (enExample)
CL (2) CL2014000209A1 (enExample)
EA (1) EA201490377A1 (enExample)
HK (2) HK1198279A1 (enExample)
IL (1) IL251397A0 (enExample)
IN (1) IN2014MN00333A (enExample)
MX (1) MX2014001050A (enExample)
PE (1) PE20142319A1 (enExample)
SG (1) SG10201606191PA (enExample)
UY (1) UY34358A (enExample)
WO (1) WO2013016684A1 (enExample)
ZA (1) ZA201401371B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
KR20130006640A (ko) * 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
EA201290860A1 (ru) 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
EP3043647A4 (en) * 2013-09-12 2017-05-10 Teva Pharmaceutical Industries Ltd. Gene expression biomarkers of laquinimod responsiveness
UY35748A (es) * 2013-09-27 2015-04-30 Teva Pharma Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple
WO2015073697A1 (en) * 2013-11-15 2015-05-21 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
US20150361757A1 (en) * 2014-06-17 2015-12-17 Baker Hughes Incoporated Borehole shut-in system with pressure interrogation for non-penetrated borehole barriers
WO2016044103A1 (en) * 2014-09-16 2016-03-24 Teva Pharmaceutical Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
WO2017019862A1 (en) * 2015-07-30 2017-02-02 Teva Pharmaceuticals Industries Ltd. Combination formulation of laquinimod and glatiramer acetate with amino acids
SG11202010087UA (en) * 2018-04-13 2020-11-27 Mordechai Chevion Compositions and methods for treatment of demyelination
CA3157394A1 (en) 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
KR102350943B1 (ko) * 2021-07-12 2022-01-14 주식회사 바움디자인시스템즈 집적 회로에 대한 소비 전력을 예측하는 방법 및 이를 수행하는 소비 전력 예측 시스템

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
CN101466379B (zh) * 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
AU2009288108B2 (en) * 2008-09-03 2013-10-17 Teva Pharmaceutical Industries, Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
EP2493477B1 (en) * 2009-10-27 2013-10-16 Wyeth LLC Bazedoxifene formulations with antioxidants
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis

Similar Documents

Publication Publication Date Title
US11648232B2 (en) Methods and compositions for treating excessive sleepiness
JP2014530821A5 (enExample)
JP2010518122A5 (enExample)
JP7069253B2 (ja) 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
JP2013544887A5 (enExample)
HRP20140783T1 (hr) Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest
JP2005510535A5 (enExample)
JP2015512406A5 (enExample)
EP2713724A1 (en) Methods of treating multiple sclerosis and preserving and/or increasing myelin content
JP2017510607A5 (enExample)
CA2294589A1 (en) Composition for controlling mood disorders in healthy individuals
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP2010513250A5 (enExample)
TW202333733A (zh) 一種(6S)-N-[4-({(2S,5R)-5-[(R)-羥基(苯基)甲基]吡咯啶-2-基}甲基)苯基]-4-側氧-4,6,7,8-四氫吡咯并[1,2-a]嘧啶-6-甲醯胺用於夜間頻尿治療劑之醫藥製造之用途
JP2015522077A5 (enExample)
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
CA2859004A1 (en) Methods and compositions for administration of oxybutynin
CN100518775C (zh) 一种治疗咳喘的药物组合物及其制剂
JP2012502105A5 (enExample)
JP4745661B2 (ja) 統合失調症治療剤
JP2015524460A5 (enExample)
CN101677998B (zh) 包含西洛他唑的治疗精神分裂症药物
CN109464441B (zh) 3-乙酰氨基香豆素在制备治疗或预防高尿酸血症及肾损伤的药物中的应用
JP2016533323A5 (enExample)